Marietta Kirchner

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Chronic Kidney Disease

Top Venues

Medical decision making : an international journal of the Society for Medical Decision Making

Pharmaceutical statistics

Bioengineering (Basel, Switzerland)

Biometrical journal. Biometrische Zeitschrift

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher A Büsch, Marietta Kirchner, Rouven Behnisch, Meinhard Kieser
A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study. Medical decision making : an international journal of the Society for Medical Decision Making 44 (4) (2024)
Marietta Kirchner, Stefanie Schüpke, Meinhard Kieser
Optimal sample size allocation for two-arm superiority and non-inferiority trials with binary endpoints. Pharmaceutical statistics (2024)
Christopher A Büsch, Marietta Kirchner, Rouven Behnisch, Meinhard Kieser
A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study. Medical decision making : an international journal of the Society for Medical Decision Making 44 (4) (2024)
Christopher A Büsch, Marietta Kirchner, Rouven Behnisch, Meinhard Kieser
A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study. Medical decision making : an international journal of the Society for Medical Decision Making 44 (4) (2024)
Christopher A Büsch, Marietta Kirchner, Rouven Behnisch, Meinhard Kieser
A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study. Medical decision making : an international journal of the Society for Medical Decision Making (2024)
Heiko Götte, Marietta Kirchner, Johannes Krisam, Arthur Allignol, Armin Schueler, Meinhard Kieser
Estimation of treatment effects in early-phase randomized clinical trials involving external control data. Journal of biopharmaceutical statistics (2023)
Felix Stief, Anna Sohn, Lutz Vogt, Andrea Meurer, Marietta Kirchner
Characterization of Postural Sway in Women with Osteoporosis and a Control Group by Means of Linear and Nonlinear Methods. Bioengineering (Basel, Switzerland) 10 (4) (2023)
Felix Stief, Anna Sohn, Lutz Vogt, Andrea Meurer, Marietta Kirchner
Characterization of Postural Sway in Women with Osteoporosis and a Control Group by Means of Linear and Nonlinear Methods. Bioengineering (Basel, Switzerland) 10 (4) (2023)
Nicolas Hohmann, Martin Ronald Sprick, Azaz Ahmed, Juergen Burhenne, Marietta Kirchner, Lucian Le Cornet, Markus Kratzmann, Jacek Hajda, Albrecht Stenzinger, Karen Steindorf, Stefan Delorme, Heinz-Peter Schlemmer, Sabine Riethdorf, Ron van Schaik, Klaus Pantel, Jens Thomas Siveke, Thomas Seufferlein, Dirk Jäger, Walter Emil Haefeli, Flavia Carla Meotti, Christoph Springfeld
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy. Clinical and translational science (2023)
Heiko Götte, Marietta Kirchner, Johannes Krisam, Arthur Allignol, Francois-Xavier Lamy, Armin Schueler, Meinhard Kieser
An adaptive design for early clinical development including interim decision for single-arm trial with external controls or randomized trial. Pharmaceutical statistics 21 (3) (2022)
Peter Hoffmann, David Lamerz, Petra Hill, Marietta Kirchner, Annika Gauss
Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn's Disease: On the Way to Personalized Medicine? Genes 12 (6) (2021)
Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, Thomas Brodowicz, Bernd Kasper, Peter Reichardt, Stephan Richter, Lars Hartwin Lindner, Joanna Szkandera, Viktor Gruenwald, Maxim Kebenko, Marietta Kirchner, Peter Hohenberger
Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06). Cancers 13 (6) (2021)
Karl-Friedrich Kowalewski, Marie Angela Sidoti Abate, Manuel Neuberger, Marietta Kirchner, Regina Krisam, Luisa Egen, Caelan Max Haney, Fabian Siegel, Maurice-Stephan Michel, Patrick Honeck, Philipp Nuhn, Niklas Westhoff, Maximilian Christian Kriegmair
ROBOCOP II (ROBOtic assisted versus conventional open partial nephrectomy) randomised, controlled feasibility trial: clinical trial protocol. BMJ open 11 (11) (2021)
Heiko Götte, Junyuan Xiong, Marietta Kirchner, Hakan Demirtas, Meinhard Kieser
Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival. Pharmaceutical statistics 19 (6) (2020)
Johannes Holle, Marietta Kirchner, Jürgen Okun, Aysun K Bayazit, Lukasz Obrycki, Nur Canpolat, Ipek Kaplan Bulut, Karolis Azukaitis, Ali Duzova, Bruno Ranchin, Rukshana Shroff, Cengiz Candan, Jun Oh, Günter Klaus, Francesca Lugani, Charlotte Gimpel, Rainer Büscher, Alev Yilmaz, Esra Baskin, Hakan Erdogan, Ariane Zaloszyc, Gül Özcelik, Dorota Drozdz, Augustina Jankauskiene, Francois Nobili, Anette Melk, Uwe Querfeld, Franz Schaefer, null null
Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children. PloS one 15 (10) (2020)
Heiko Götte, Marietta Kirchner, Meinhard Kieser
Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpoint. Biometrical journal. Biometrische Zeitschrift 62 (3) (2019)